{"id":1914,"date":"2023-11-10T16:10:00","date_gmt":"2023-11-10T15:10:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1914"},"modified":"2024-04-10T16:14:02","modified_gmt":"2024-04-10T14:14:02","slug":"41-liecivo-daratumumab-darzalex-v-kombinacii-s-lenalidomidom-a-dexametazonom-na-liecbu-dospelych-pacientov-s-novodiagnostikovanym-mnohopocetnym-myelomom-ktori-nie-su-vhodni-na-autolognu-transplant","status":"publish","type":"post","link":"https:\/\/niho.sk\/en\/41-liecivo-daratumumab-darzalex-v-kombinacii-s-lenalidomidom-a-dexametazonom-na-liecbu-dospelych-pacientov-s-novodiagnostikovanym-mnohopocetnym-myelomom-ktori-nie-su-vhodni-na-autolognu-transplant\/","title":{"rendered":"41: Lie\u010divo daratumumab (Darzalex) v kombin\u00e1cii s lenalidomidom a dexametaz\u00f3nom na lie\u010dbu dospel\u00fdch pacientov s novodiagnostikovan\u00fdm mnohopo\u010detn\u00fdm myel\u00f3mom, ktor\u00ed nie s\u00fa vhodn\u00ed na autol\u00f3gnu transplant\u00e1ciu kme\u0148ov\u00fdch buniek"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Mnohopo\u010detn\u00fd myel\u00f3m (MM) je v s\u00fa\u010dasnosti nekurat\u00edvne ochorenie, ktor\u00e9 vytv\u00e1ra ve\u013ek\u00fa z\u00e1\u0165a\u017e na pacientov po fyzickej aj psychickej str\u00e1nke. Ochorenie m\u00e1 tie\u017e v\u00fdrazn\u00fd dopad na d\u013a\u017eku pre\u017e\u00edvania a kvalitu \u017eivota pacientov. <\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      DARZALEX je liek na lie\u010dbu n\u00e1dorov\u00e9ho ochorenia, ktor\u00fd obsahuje lie\u010divo daratumumab. Patr\u00ed do skupiny liekov naz\u00fdvan\u00fdch \u201emonoklon\u00e1lne protil\u00e1tky\u201c. Monoklon\u00e1lne protil\u00e1tky s\u00fa prote\u00edny, ktor\u00e9 boli navrhnut\u00e9 tak, aby rozpoznali a naviazali sa na \u0161pecifick\u00e9 miesta v tele. Daratumumab bol navrhnut\u00fd tak, aby sa naviazal na \u0161pecifick\u00e9 n\u00e1dorov\u00e9 bunky vo va\u0161om tele, aby mohol v\u00e1\u0161 imunitn\u00fd syst\u00e9m n\u00e1dorov\u00e9 bunky zni\u010di\u0165.<\/p>\n\n\n\n

      Darzalex bol registrovan\u00fd v Eur\u00f3pskej \u00fanii pre hodnoten\u00fa indik\u00e1ciu v okt\u00f3bri 2019.<\/p>\n\n\n\n

        \n
      1. Ako sa na hodnoten\u00e9 lie\u010divo pozeraj\u00fa odborn\u00edci?\u00a0<\/strong><\/li>\n<\/ol>\n\n\n\n

        Na z\u00e1klade vyjadren\u00ed odborn\u00edkov maj\u00fa pacienti na Slovensku obmedzen\u00e9 mo\u017enosti lie\u010dby pod\u013ea najnov\u0161\u00edch medzin\u00e1rodn\u00fdch postupov. Odborn\u00edci pova\u017euj\u00fa za d\u00f4le\u017eit\u00e9 ma\u0165 mo\u017enos\u0165 pou\u017e\u00edva\u0165 v\u0161etky najnov\u0161ie lie\u010debn\u00e9 re\u017eimy u\u017e v prvej l\u00ednii lie\u010dby MM.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Janssen – Cilag International N.V. (BEL)) podal \u017eiados\u0165 o zaradenie lie\u010diva daratumumab (Darzalex) v kombin\u00e1cii s lenalidomidom a dexametaz\u00f3nom na lie\u010dbu dospel\u00fdch pacientov s novodiagnostikovan\u00fdm mnohopo\u010detn\u00fdm myel\u00f3mom, ktor\u00ed nie s\u00fa vhodn\u00ed na autol\u00f3gnu transplant\u00e1ciu kme\u0148ov\u00fdch buniek.<\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Darzalex v predmetnej indik\u00e1ci\u00ed, pokia\u013e dr\u017eite\u013e registr\u00e1cie uprav\u00ed po\u017eadovan\u00fa v\u00fd\u0161ku \u00fahrady tak, aby sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti.<\/p>","protected":false},"excerpt":{"rendered":"

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Darzalex v predmetnej indik\u00e1ci\u00ed, pokia\u013e dr\u017eite\u013e registr\u00e1cie…<\/p>","protected":false},"author":3,"featured_media":1720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[15,14],"class_list":["post-1914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-daratumumab","tag-darzalex"],"_links":{"self":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1914"}],"version-history":[{"count":0,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media\/1720"}],"wp:attachment":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}